Condition: Cytomegalovirus Cell Mediated Immunity · Hematopoietic Cell Transplant · Sponsor: M.D. Anderson Cancer Center
The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transplant patients avoid post-treatment CMV infections better than taking letermovir every day without interruption.
This description comes directly from the study's public registry record.
Fareed Khawaja, MBBS · (281) 610-0253 · fkhawaja@mdanderson.org
Always discuss trial participation with your own doctor first.
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06639854